2-amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide(WXC04788) manufacturers
- Gartisertib
-
- $1070.00
-
2026-07-14
- CAS:1613191-99-3
- Purity: 99.52%
- Supply Ability: 10g
- Gartisertib
-
- $1130.00
-
2025-05-29
- CAS:1613191-99-3
- Purity: 99.52%
- Supply Ability: 10g
|
| | 2-amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide(WXC04788) Basic information |
| | 2-amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide(WXC04788) Chemical Properties |
| density | 1+-.0.1 g/cm3(Predicted) | | form | Solid | | pka | 4.89±0.46(Predicted) | | color | Light yellow to yellow |
| | 2-amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide(WXC04788) Usage And Synthesis |
| Uses | 2-Amino-6-fluoro-N-[5-fluoro-4-[4-[[4-(oxetan-3-yl)piperazin-1-yl]carbonyl]-1-piperidyl]-3-pyridyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide is an ATP-competitive and selective ATR inhibitor. Exhibits antitumor activity. Useful for monotherapy. | | in vivo | In monotherapy efficacy studies Gartisertib shows tumor stasis to regression in tumor models with alternative lengthening of telomeres (ALT). In combination with PARP inhibitors, tumor regression could be observed in triple-negative breast cancer xenograft models[1]. | | IC 50 | ATR: <150 pM (Ki) |
| | 2-amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide(WXC04788) Preparation Products And Raw materials |
|